Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 10/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690899 | 0.81 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL607503 | 0.79 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5468494 | 0.79 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL96701 | 0.79 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1260631 | 0.79 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25981474 | 0.78 | MMP1 (0.40) | — | |
| SCHEMBL1964905 | 0.77 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14016296 | 0.77 | CYP2D6 (0.51) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14881066 | 0.77 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21811455 | 0.77 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381833-B2 | Process for producing 1,2-cis-2-fluorocyclopropane-1-carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | HACL2, B2M, CA1 | CYP2D6 1440/4885HDAC3 1541/4885HDAC1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.